CN111278300A - 包含猴头菇的益生菌组合物 - Google Patents
包含猴头菇的益生菌组合物 Download PDFInfo
- Publication number
- CN111278300A CN111278300A CN201780073282.XA CN201780073282A CN111278300A CN 111278300 A CN111278300 A CN 111278300A CN 201780073282 A CN201780073282 A CN 201780073282A CN 111278300 A CN111278300 A CN 111278300A
- Authority
- CN
- China
- Prior art keywords
- lactic acid
- probiotic composition
- bifidobacterium
- lactobacillus
- acid bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 72
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 61
- 240000000588 Hericium erinaceus Species 0.000 title claims description 52
- 235000007328 Hericium erinaceus Nutrition 0.000 title claims description 52
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 128
- 241000894006 Bacteria Species 0.000 claims abstract description 68
- 239000000843 powder Substances 0.000 claims abstract description 67
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 64
- 239000004310 lactic acid Substances 0.000 claims abstract description 64
- 239000000284 extract Substances 0.000 claims abstract description 58
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 32
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 32
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 26
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 22
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 22
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 22
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 22
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 20
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 20
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 17
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 17
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 17
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 8
- 206010010774 Constipation Diseases 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 14
- 239000003094 microcapsule Substances 0.000 claims description 12
- 208000004998 Abdominal Pain Diseases 0.000 claims description 11
- 206010012735 Diarrhoea Diseases 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 7
- 241000194031 Enterococcus faecium Species 0.000 claims description 6
- 244000057717 Streptococcus lactis Species 0.000 claims description 6
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 6
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 5
- 241000186012 Bifidobacterium breve Species 0.000 claims description 5
- 241000194032 Enterococcus faecalis Species 0.000 claims description 5
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 5
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 5
- 230000013872 defecation Effects 0.000 claims description 5
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000012046 mixed solvent Substances 0.000 description 10
- 229910001220 stainless steel Inorganic materials 0.000 description 9
- 239000010935 stainless steel Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 240000000599 Lentinula edodes Species 0.000 description 7
- 230000007413 intestinal health Effects 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 235000001715 Lentinula edodes Nutrition 0.000 description 5
- 239000000287 crude extract Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 240000006499 Flammulina velutipes Species 0.000 description 3
- 235000016640 Flammulina velutipes Nutrition 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical class O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005709 nerve cell growth Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及益生菌组合物,其包含乳酸菌粉末、蘑菇提取物及低聚果糖,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
Description
技术领域
本发明涉及包含猴头菇的益生菌组合物。
背景技术
最近,肠道内微生物对人体的身体健康及精神健康带来的影响众所周知,正在进行着使肠道内有益微生物的种类多样化并增加其活性的努力。
在这些努力中,最普通且广泛使用的是益生菌的摄取。益生菌(probiotics)是指对人体、动物体等的健康带来有益的影响的生菌,其中,通常使用乳杆菌、双歧杆菌、乳球菌等乳酸菌。
但是,这些益生菌不仅根据菌的种类对人体带来的影响不同,而且存在摄取的益生菌活着到达所需的身体部位,即,活着到达小肠、大肠等的概率低的问题。对此,为了增加益生菌的体内活性及寿命,将作为益生菌的食物的多个有机物,即,益生元与益生菌一同摄取。
一方面,与普通蘑菇相比,猴头菇具有多种活性多糖,其中,半乳糖木糖葡聚糖和甘露葡糖硅烷由于含有特殊活性多糖体,因而具有卓越的抗肿瘤性。并且,仅在猴头菇所具有的作为多糖体的猴头菇多糖(Hericium Polysaccharide)通过攻击细菌或病毒或存在缺陷的细胞来强化巨噬细胞或淋巴细胞,以此防止发生大肠癌或胃癌,而且上述猴头菇多糖对各种胃炎均有效。猴头菇含有非常丰富的仅在几种药用蘑菇中存在的庆西素(OleanolicAcid),因此具有通过保护胃壁来防止发生胃溃疡和胃炎的效果。尤其,事实表明,猴头菇具有促进神经细胞增殖因子(Nerve Growth Factor)的生物合成的猴头菌酮(Hericenone D)和猴头菌多醇(Erinacine C)。并且公开了这具有优秀的预防和治疗老年痴呆的效果。并且,含在猴头菇的猴头菌酮和猴头菌多醇可通过血液来向大脑传递,并促进增殖因子的合成,因此可成为痴呆、阿尔兹海默症的有效治疗方法。并且,以大脑内荷尔蒙肾上腺素四倍的神经细胞增殖因子合成促进作用阻止神经细胞(神经元)的消失并促进神经细胞(神经元)的合成,由此也可对成长期儿童或青少年的智力发展起到很大的作用。尤其,根据猴头菇所含的钾、钙、镁等的无机质进入体内来与酶相互作用后排出的离子化代谢信号,如肽等的低分子物质被细胞摄取,最终恢复β细胞的功能并分泌出胰岛素。即,通过上述一系列的作用可知,胰岛素的正常分泌和血糖值的降低可以改善糖尿病,从而也可用作肝功能改善剂。
本发明人在研究生物活性增加的益生菌的过程中,确认到当一同摄取特定的多个益生菌与猴头菇提取物时,肠道健康得到增进,并且完成了本发明。
发明内容
发明所要解决的问题
本发明的目的在于,提供生物活性增加的益生菌组合物。
用于解决问题的方案
为了实现上述目的,本发明提供益生菌组合物,其包含乳酸菌粉末、蘑菇提取物及低聚果糖,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
发明效果
本发明的益生菌组合物通过增进肠道健康来改善便秘并改善腹泻及腹痛,从而使排便顺畅。
具体实施方式
本发明涉及益生菌组合物,其包含乳酸菌粉末、蘑菇提取物及低聚果糖,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
并且,本发明涉及便秘改善方法,上述便秘改善方法包括使对象摄取包含乳酸菌粉末、蘑菇提取物及低聚果糖的益生菌组合物的步骤,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
并且,本发明涉及腹泻及腹痛的改善方法,上述腹泻及腹痛的改善方法包括使对象摄取包含乳酸菌粉末、蘑菇提取物及低聚果糖的益生菌组合物的步骤,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
并且,本发明涉及益生菌组合物的便秘改善用用途,上述益生菌组合物包含乳酸菌粉末、蘑菇提取物及低聚果糖,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
并且,本发明涉及益生菌组合物的腹泻及腹痛改善用途,上述益生菌组合物包含乳酸菌粉末、蘑菇提取物及低聚果糖,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
以下,详细地说明本发明。
乳酸菌粉末
本发明的乳酸菌粉末包含选自由乳酸乳球菌(Lactococuus lactis)、屎肠球菌(Enterococcus faecium)、粪肠球菌(faecalis)、嗜热链球菌(Streptococcusthermophilus)、乳酸双歧杆菌、长双歧杆菌、两岐双岐杆菌(bifidum)、短双歧杆菌(breve)、动物双歧杆菌乳酸亚种(animalis ssp.lactis)、嗜酸乳杆菌、干酪乳杆菌(casei)、加氏乳杆菌(gasseri)、德氏乳杆菌保加利亚亚种(delbrueckiissp.bulgaricus)、瑞士乳杆菌(helveticus)、发酵乳杆菌(fermentum)、副干酪乳杆菌(paracasei)、罗伊氏乳杆菌(reuteri)、唾液乳杆菌(salivarius)、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。优选地,本发明的乳酸菌粉末包含乳酸乳球菌、屎肠球菌、粪肠球菌、嗜热链球菌、乳酸双歧杆菌、长双歧杆菌、两岐双岐杆菌、短双歧杆菌、动物双歧杆菌乳酸亚种、嗜酸乳杆菌、干酪乳杆菌、加氏乳杆菌、德氏乳杆菌保加利亚亚种、瑞士乳杆菌、发酵乳杆菌、副干酪乳杆菌、罗伊氏乳杆菌、唾液乳杆菌、植物乳杆菌及鼠李糖乳杆菌。更优选地,本发明的乳酸菌粉末包含乳酸乳球菌、屎肠球菌、粪肠球菌、嗜热链球菌、乳酸双歧杆菌、长双歧杆菌、两岐双岐杆菌、短双歧杆菌、动物双歧杆菌乳酸亚种、嗜酸乳杆菌、干酪乳杆菌、加氏乳杆菌、德氏乳杆菌保加利亚亚种、瑞士乳杆菌、发酵乳杆菌、副干酪乳杆菌、罗伊氏乳杆菌、唾液乳杆菌、植物乳杆菌、鼠李糖乳杆菌及乳酸双歧杆菌双微胶囊粉末。
此时,除上述乳酸双歧杆菌双微胶囊粉末以外的剩余的多种乳酸菌为非双微胶囊。非双微胶囊的上述多种乳酸菌能够以其他胶囊形态涂敷,也可以未被涂敷。
本发明的乳酸菌粉末以1:0.5至1.5的重量比包含乳酸双歧杆菌双微胶囊粉末和非双微胶囊的乳酸双歧杆菌,优选地,以1:0.8至1.2的重量比包含,更优选地,以1:1的重量比包含。
优选地,上述乳酸双歧杆菌为乳酸双歧杆菌CBG-C10(保藏编号:KACC 15464)。优选地,上述长双歧杆菌为长双歧杆菌CBG-C11(保藏编号:KCTC 11979BP)。优选地,上述嗜酸乳杆菌为嗜酸乳杆菌CBG-C13(保藏编号:KACC 91980P)。优选地,上述植物乳杆菌为植物乳杆菌JBMI F5(保藏编号:KACC 91638P)。优选地,上述鼠李糖乳杆菌为鼠李糖乳杆菌CBG-C14(保藏编号:KACC 91981P)。
尤其,优选地,上述本发明的益生菌组合物使用嗜酸乳杆菌CBG-C13(保藏编号:KACC 91980P)及鼠李糖乳杆菌CBG-C14(保藏编号:KACC 91981P)。
并且,韩国授权专利10-1446309号、韩国授权专利10-1401530号及韩国授权专利10-1274467号以及韩国专利申请10-2015-0023370号及韩国专利申请10-2015-0023375号的全部内容均包含在本申请的说明书中作为参考。
蘑菇提取物
优选地,本发明的蘑菇提取物为猴头菇提取物。更优选地,本发明的蘑菇提取物为猴头菇子实体的提取物、猴头菇菌丝体的提取物或猴头菇子实体及菌丝体的提取物。优选地,上述提取物为水或碳原子数为5以下的低级乙醇的提取物,更优选为水或碳原子数为3以下的低级醇的提取物,最优选为乙醇提取物。此时,优选地,上述乙醇提取物为利用包含乙醇和水的溶剂来进行提取的提取物。通过添加上述猴头菇提取物来使本发明的益生菌组合物在生物体内的活性增加。优选地,当制备本发明的益生菌组合物时,一同使用糊精。此时,以10:15至30重量比混合糊精和猴头菇提取物,有利于防止因猴头菇的高粘度而导致的益生菌组合物的聚集现象,并且有利于实现均匀且干燥的粉末化。
益生菌组合物
本发明的益生菌组合物使肠道内微生物的种类多样化,并且增加肠道内有益微生物的活性,而且抑制肠道内有害菌的活性来增进肠道健康。本发明的益生菌组合物对于便秘的人具有改善便秘的功效,对于经常腹泻及腹痛的人具有通过减少腹泻及腹痛来改善的功效。即,本发明的益生菌组合物通过增进肠道健康来帮助排便活动。
对象
摄取本发明的益生菌组合物的对象为包括人类的哺乳动物。上述对象包括便秘的人、腹泻及腹痛频繁的人、经常有肠道问题的人,但不限定于此。
优选地,本发明的益生菌组合物为粉末形态,可通过如片剂、硬质胶囊剂或软质胶囊剂、液剂、悬浮剂等口服给药用制剂的形态来使用,这些制剂可使用可接受的常规的载体,例如,在口服给药制剂的情况下,可通过使用赋形剂、结合剂、崩解剂、滑润剂、加溶剂、助悬剂、保鲜剂或增量剂等来配制。
参照详细后述的实施例,使本发明的优点、特征及实现这些的方法明确。但是,本发明并不限定于以下揭示的实施例,而是将以互不相同的多种形态体现,并且本实施例仅使本发明的揭示完整,为了向本发明所属领域普通技术人员完整地说明发明的范畴而提供,本发明仅是通过发明要求保护范围来定义。
材料及方法
作为多种乳酸菌,使用下列表1的多种乳酸菌,从科倍健(chebigen)株式会社购入多种乳酸菌并使用。并且,从科倍健株式会社购入乳酸双歧杆菌CBG-C10的双微胶囊粉末(Bifidobacterium lactis)并使用。其中,嗜酸乳杆菌CBG-C13(保藏编号:KACC 91980P)及鼠李糖乳杆菌CBG-C14(保藏编号:KACC 91981P)具有耐酸性、耐胆汁性及抗生素耐药性,尤其在肠道内有益菌增殖及有害菌抑制方面具有优秀的效果,并且帮助排便活动的能力非常优秀。
表1
作为猴头菇的子实体及菌丝体,购入市面上销售的韩国产猴头菇的子实体及菌丝体并使用。作为香菇及金针菇,同样购入市面上销售的韩国产香菇及金针菇并使用。
制备例1:制备猴头菇子实体粉末
在清洗干净10kg的猴头菇子实体后,在圆筒形不锈钢减压干燥机中以40℃至60℃的温度干燥20小时以上,来制备水分含量为3%以下的猴头菇子实体干燥体。用针磨机(pinmill)粉碎所制备的猴头菇子实体干燥体,来制备出约为50目(mesh)的猴头菇子实体粉末。
制备例2:制备猴头菇菌丝体粉末
在清洗干净10kg的猴头菇菌丝体后,在圆筒形不锈钢减压干燥机中以40℃至60℃的温度干燥20小时以上,来制备水分含量为3%以下的猴头菇菌丝体干燥体。用针磨机粉碎所制备的猴头菇菌丝体干燥体,来制备约为50目的猴头菇菌丝体粉末。
制备例3:制备猴头菇提取物A
将5kg的在制备例1中制备的猴头菇子实体粉末放入2.5L的乙醇和10L的水的混合溶剂后,在设有逆流(Reflux)装置的100L的不锈钢容器中以90℃至98℃的温度加热24小时来进行提取。并且,对上述粗提取物用无纺布过滤器来进行过滤之后,以减压蒸馏方式蒸馏混合溶剂,以此制备500mL的浓缩的液体形态的猴头菇子实体提取物,并且对其进行热风干燥后进行粉碎,从而制备猴头菇提取物A。
制备例4:制备猴头菇提取物B
将5kg的在制备例2中制备的猴头菇菌丝体粉末放入2.5L的乙醇和10L的水的混合溶剂后,在设有逆流装置的100L的不锈钢容器中以90℃至98℃的温度加热24小时来进行提取。并且,对上述粗提取物用无纺布过滤器来进行过滤之后,以减压蒸馏方式蒸馏混合溶剂,以此制备500mL的浓缩的液体形态的猴头菇菌丝体提取物,并且对其进行热风干燥后进行粉碎,从而制备猴头菇提取物B。
制备例5:制备猴头菇提取物C
混合3.5kg的在制备例1中制备的猴头菇子实体粉末和1.5kg的在制备例2中制备的猴头菇菌丝体粉末来制备猴头菇粉末混合物。将5kg的上述混合物放入2.5L的乙醇和10L的水的混合溶剂后,在设有逆流装置的100L的不锈钢容器中以90℃至98℃的温度加热24小时来进行提取。并且,对上述粗提取物用无纺布过滤器来进行过滤之后,以减压蒸馏方式蒸馏混合溶剂,以此制备500mL的浓缩的液体形态的猴头菇菌丝体及猴头菇子实体混合物的提取物,并且对其进行热风干燥后进行粉碎,从而制备猴头菇提取物C。
制备例6:制备香菇提取物粉末
在清洗干净10kg的香菇后,在圆筒形不锈钢减压干燥机中以40℃至60℃的温度干燥20小时以上,来制备水分含量为3%以下的香菇干燥体后进行粉碎。将5kg的香菇粉末放入2.5L的乙醇和10L的水的混合溶剂后,在设有逆流装置的100L的不锈钢容器中以90℃至98℃的温度加热24小时来进行提取。并且,对上述粗提取物用无纺布过滤器来进行过滤之后,以减压蒸馏方式蒸馏混合溶剂,以此制备500mL的浓缩的液体形态的香菇提取物,并且对其进行热风干燥后进行粉碎,从而制备香菇提取物粉末。
制备例7:制备金针菇提取物粉末
在清洗干净10kg的金针菇后,在圆筒形不锈钢减压干燥机中以40℃至60℃的温度干燥20小时以上,来制备水分含量为3%以下的香菇干燥体后进行粉碎。将5kg的金针菇粉末放入2.5L的乙醇和10L的水的混合溶剂后,在设有逆流装置的100L的不锈钢容器中以90℃至98℃的温度加热24小时来进行提取。并且,对上述粗提取物用无纺布过滤器来进行过滤之后,以减压蒸馏方式蒸馏混合溶剂,以此制备500mL的浓缩的液体形态的金针菇提取物,并且对其进行热风干燥后进行粉碎,从而制备金针菇提取物粉末。
实施例1
制备乳酸菌粉末
在100重量份的蒸馏水中,加入10重量份的牛奶并混合后进行杀菌。在其接种2重量份的乳酸菌并在38℃的温度下培养10小时,并且对其进行冷冻干燥来制备乳酸菌粉末。
此时,作为上述乳酸菌,使用乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌、鼠李糖乳杆菌及乳酸双歧杆菌双微胶囊粉末,并且以相同的重量比混合上述六个种类来使用。
制备益生菌组合物
在100重量份的上述乳酸菌粉末混合250重量份的制备例3的猴头菇提取物A、10重量份的维生素C、50重量份的低聚果糖、20重量份的无水结晶葡萄糖、10重量份的塔格糖、10重量份的酶改质甜菊糖(Enzymatically Modified Stevia)、10重量份的浆果味粉末、100重量份的糊精、10重量份的二氧化硅来制备益生菌组合物。
实施例2
除了用猴头菇提取物B代替猴头菇提取物A外,以与实施例1相同的方法制备益生菌组合物。
实施例3
除了用猴头菇提取物C代替猴头菇提取物A外,以与实施例1相同的方法制备益生菌组合物。
实施例4
除了用香菇提取物粉末代替猴头菇提取物A外,以与实施例1相同的方法制备益生菌组合物。
实施例5
除了用金针菇提取物粉末代替猴头菇提取物A外,以与实施例1相同的方法制备益生菌组合物。
实施例6
除了未使用猴头菇提取物A外,以与实施例1相同的方法制备益生菌组合物。即,在实施例6中,作为益生元,完全未使用蘑菇提取物。
实施例7
当制备乳酸菌粉末时,除了未使用乳酸双歧杆菌双微胶囊粉末外,以与实施例1相同的方法制备益生菌组合物。
实施例8
除了当制备乳酸菌粉末时未使用嗜酸乳杆菌CBG-C13(保藏编号:KACC91980P)外,以与实施例1相同的方法制备益生菌组合物。
实施例9
除了当制备乳酸菌粉末时未使用鼠李糖乳杆菌CBG-C14(保藏编号:KACC91981P)外,以与实施例1相同的方法制备益生菌组合物。
实验例1
以90名便秘的16岁至42岁的男女为对象,评价本发明的益生菌组合物的促进排便能力。此时,将实施例1至实施例9的益生菌组合物向各10名每日摄取两次并记录排便频率。一次摄取量为60g。
并且,经过2个月后,与实验前进行比较来评价排便次数的改善与否。其结果,确认到实施例1至实施例4的益生菌组合物对有便秘症状的人的改善便秘的能力优秀。并且,实施例7及实施例8也呈现出具有便秘改善能力,但是其根据个人稍有差异(表2)。
表2
实验例2
以36名经常腹痛或因肠道问题而经常腹泻的18岁至43岁的男女为对象,评价本发明的益生菌组合物的肠道健康改善能力。此时,将实施例1至实施例9的益生菌组合物向各10名每日摄取两次并记录排便频率。一次摄取量为60g。
并且,经过2个月后,与实验前进行比较来评价腹泻及腹痛次数的改善与否。其结果,呈现出实施例1至实施例3的肠道健康改善能力优秀。此外,实施例7也呈现出具有肠道健康改善能力,但是确认到对其未反应的人也相当多(表3)。
表3
实验例3
制备乳酸菌粉末
在100重量份的蒸馏水中,加入10重量份的牛奶并混合后进行杀菌。在其接种2重量份的乳酸菌并在38℃的温度下培养10小时,并且对其进行冷冻干燥来制备乳酸菌粉末。
此时,作为上述乳酸菌,以1:1的重量比混合上述表1的乳酸菌混合物和市面上销售的乳酸菌混合物来使用。
即,使用表1的乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌、鼠李糖乳杆菌及乳酸双歧杆菌双微胶囊粉末,并且以相同的重量比混合上述六个种类来制备混合物。
并且,购入市面上销售的乳酸乳球菌、屎肠球菌、粪肠球菌、嗜热链球菌、两岐双岐杆菌、短双歧杆菌、动物双歧杆菌乳酸亚种、干酪乳杆菌、加氏乳杆菌、德氏乳杆菌保加利亚亚种、瑞士乳杆菌、发酵乳杆菌、副干酪乳杆菌、罗伊氏乳杆菌及唾液乳杆菌粉末,将这些市面上销售的多种乳酸菌以相同的重量比混合。
并且,以1:2的重量比混合上述表1的乳酸菌混合物及市面上销售的乳酸菌混合物来制备乳酸菌混合物粉末。
制备益生菌组合物
在100重量份的上述乳酸菌粉末混合250重量份的制备例3的猴头菇提取物A、10重量份的维生素C、50重量份的低聚果糖、20重量份的无水结晶葡萄糖、10重量份的塔格糖、10重量份的酶改质甜菊糖、10重量份的浆果味粉末、10重量份的二氧化硅来制备益生菌组合物。
以20名便秘的60岁至84岁的男女为对象,评价上述益生菌组合物的促进排便能力。此时,将上述益生菌组合物每日摄取两次并记录排便频率。一次摄取量为60g。
其结果,在20名受访者中的4名受访者的便秘明显得到改善,11名受访者的便秘在一定程度上得到改善。
工业利用性
本发明涉及益生菌组合物,其包含乳酸菌粉末、蘑菇提取物及低聚果糖,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
PCT/RO/134表
Claims (15)
1.一种益生菌组合物,其特征在于,包含乳酸菌粉末、蘑菇提取物及低聚果糖,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
2.根据权利要求1所述的益生菌组合物,其特征在于,还包含乳酸双歧杆菌双微胶囊粉末。
3.根据权利要求1所述的益生菌组合物,其特征在于,上述嗜酸乳杆菌为嗜酸乳杆菌CBG-C13,其保藏编号为KACC 91980P。
4.根据权利要求1所述的益生菌组合物,其特征在于,上述鼠李糖乳杆菌为鼠李糖乳杆菌CBG-C14,其保藏编号为KACC 91981P。
5.根据权利要求1所述的益生菌组合物,其特征在于,上述乳酸菌粉末以1:0.5至1.5的重量比包含乳酸双歧杆菌双微胶囊粉末和非双微胶囊的乳酸双歧杆菌。
6.根据权利要求1所述的益生菌组合物,其特征在于,具有便秘改善能力。
7.根据权利要求1所述的益生菌组合物,其特征在于,具有腹泻及腹痛的改善能力。
8.根据权利要求1所述的益生菌组合物,其特征在于,有助于排便活动。
9.根据权利要求1所述的益生菌组合物,其特征在于,上述蘑菇提取物为猴头菇提取物。
10.根据权利要求1所述的益生菌组合物,其特征在于,上述蘑菇提取物为猴头菇子实体的提取物。
11.根据权利要求1所述的益生菌组合物,其特征在于,上述乳酸菌粉末还包含乳酸乳球菌、屎肠球菌、粪肠球菌、嗜热链球菌、两岐双岐杆菌、短双歧杆菌、动物双歧杆菌乳酸亚种、干酪乳杆菌、加氏乳杆菌、德氏乳杆菌保加利亚亚种、瑞士乳杆菌、发酵乳杆菌、副干酪乳杆菌、罗伊氏乳杆菌及唾液乳杆菌。
12.一种便秘改善方法,其特征在于,包括使对象摄取包含乳酸菌粉末、蘑菇提取物及低聚果糖的益生菌组合物的步骤,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
13.一种腹泻及腹痛的改善方法,其特征在于,包括使对象摄取包含乳酸菌粉末、蘑菇提取物及低聚果糖的益生菌组合物的步骤,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
14.一种益生菌组合物的便秘改善用用途,其特征在于,上述益生菌组合物包含乳酸菌粉末、蘑菇提取物及低聚果糖,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
15.一种益生菌组合物的腹泻及腹痛的改善用用途,其特征在于,上述益生菌组合物包含乳酸菌粉末、蘑菇提取物及低聚果糖,上述乳酸菌粉末包含选自由乳酸双歧杆菌、长双歧杆菌、嗜酸乳杆菌、植物乳杆菌及鼠李糖乳杆菌组成的组中的乳酸菌。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160124270A KR101765559B1 (ko) | 2016-09-27 | 2016-09-27 | 노루궁뎅이버섯을 포함하는 프로바이오틱스 조성물 |
KR10-2016-0124270 | 2016-09-27 | ||
PCT/KR2017/001729 WO2018062643A1 (ko) | 2016-09-27 | 2017-02-16 | 노루궁뎅이버섯을 포함하는 프로바이오틱스 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111278300A true CN111278300A (zh) | 2020-06-12 |
Family
ID=59653804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780073282.XA Pending CN111278300A (zh) | 2016-09-27 | 2017-02-16 | 包含猴头菇的益生菌组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11229672B2 (zh) |
KR (1) | KR101765559B1 (zh) |
CN (1) | CN111278300A (zh) |
TW (1) | TW201834673A (zh) |
WO (1) | WO2018062643A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113456704A (zh) * | 2021-06-22 | 2021-10-01 | 四川省农业科学院土壤肥料研究所 | 一种具有改善肠胃功效的药物组合物及其制备方法和应用 |
CN115153030A (zh) * | 2022-09-08 | 2022-10-11 | 同芙集团(中国)股份有限公司 | 一种益生菌组合物及其应用、益生菌产品及其制备方法 |
CN115462532A (zh) * | 2022-07-28 | 2022-12-13 | 纽崔丝达食品科技(上海)有限公司 | 一种治疗妊娠呕吐的活性益生菌配方及其制备方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102083067B1 (ko) | 2017-12-29 | 2020-04-28 | 산청기능성콩 영농조합법인 | 산채복합 추출물을 함유하는 항염증 활성이 있는 프리바이오틱스를 갖는 프로바이오틱스 조성물 및 이의 제조방법 |
KR102029263B1 (ko) | 2018-05-16 | 2019-11-08 | 주식회사 비피도 | 베타-엘-푸코피라노실-(1→3)-옥시-디-갈락토피라노오스를 포함하는 프리바이오틱스 조성물 |
CN109247570A (zh) * | 2018-10-25 | 2019-01-22 | 黑龙江惊哲森林农业科技开发有限责任公司 | 一种猴头菇胃动力酵素及其制备方法 |
CN109619540A (zh) * | 2019-02-22 | 2019-04-16 | 山东探克生物科技股份有限公司 | 一种具有润肠通便作用的益生菌组合物及其制备方法和应用 |
KR102119133B1 (ko) | 2019-05-02 | 2020-06-26 | 선정완 | 유산균 분말 및 노니 분말을 포함하는 프로바이오틱스 조성물 |
CN111840336A (zh) * | 2020-07-15 | 2020-10-30 | 西安小天使生命营养科学健康研究院有限公司 | 益生菌水苏糖及其制备工艺 |
CN114832021A (zh) * | 2022-05-17 | 2022-08-02 | 比菲德(北京)生物科技有限公司 | 一种含有人体同源菌株的益生菌粉及其应用 |
EP4342481A1 (en) * | 2022-09-26 | 2024-03-27 | Hifas da Terra SL | Use of an extract of hericium erinaceus for the treatment of vaginal and cervical diseases |
CN116262125B (zh) * | 2023-01-19 | 2023-11-14 | 哈尔滨美华生物技术股份有限公司 | 保护胃黏膜、缓解胃炎的干酪乳杆菌l7-13及其应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020192334A1 (en) * | 2001-05-07 | 2002-12-19 | Biohub Co., Ltd | Method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby |
KR20030070799A (ko) * | 2002-02-26 | 2003-09-02 | 주식회사 국순당 | 지방질, 다당류 및 단백질에 의하여 2중으로 미세캡슐화된유산균 제품의 제조방법 |
US20070128178A1 (en) * | 2002-07-23 | 2007-06-07 | Nestec S.A. | Probiotics for gut neuromuscular functions |
CN101579110A (zh) * | 2008-12-05 | 2009-11-18 | 王星丽 | 食用菌休闲食品 |
US20100166721A1 (en) * | 2006-06-09 | 2010-07-01 | Fabiola Masri | Probotic compositions and uses thereof |
JP2010285421A (ja) * | 2009-05-15 | 2010-12-24 | Daiso Co Ltd | 腸管免疫賦活能を有する乳酸菌に対する効果促進剤 |
US20120207712A1 (en) * | 2009-01-12 | 2012-08-16 | Pfizer Italia S.R.L. | Compositions Comprising Probiotic and Prebiotic Components and Mineral Salts, with Lactoferrin |
CN102919850A (zh) * | 2012-05-21 | 2013-02-13 | 孟令刚 | 一种用于营养食品及药品的组合物 |
CN104544086A (zh) * | 2015-01-23 | 2015-04-29 | 绍兴上虞宏晟技术转让服务有限公司 | 一种可改善肠道菌群的保健食品及其制备方法 |
CN104719887A (zh) * | 2013-12-23 | 2015-06-24 | 无锡伟康生物科技有限公司 | 一种调节肠道菌群复合益生菌粉 |
CN104887647A (zh) * | 2014-03-08 | 2015-09-09 | 复旦大学 | 益生菌双层微胶囊及其制备方法 |
CN105901697A (zh) * | 2016-04-15 | 2016-08-31 | 邵素英 | 一种真菌提取物益生菌功能性食品 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100589113B1 (ko) * | 2002-12-31 | 2006-06-12 | 주식회사 바름인 | 대장암 원인 장내유해세균 효소 및 헬리코박터 파이로리성장 저해 활성을 갖는 버섯 유산균 발효물의 제조 및그의 용도 |
JP2005082517A (ja) | 2003-09-08 | 2005-03-31 | Asahi Denka Kogyo Kk | βグルカン・タンパク質複合組成物 |
KR101266148B1 (ko) * | 2011-03-28 | 2013-05-21 | 재단법인 진안홍삼연구소 | 홍삼, 혼합유산균 및 올리고당류를 함유하는 조성물 및 건강기능식품 |
KR101274467B1 (ko) | 2011-08-10 | 2013-06-17 | (주)케비젠 | 유해세균에 대해 항균 활성을 갖는 락토바실러스 플란타룸 jbmi f5 균주 및 이의 용도 |
EP2675173A1 (en) | 2012-06-15 | 2013-12-18 | Thomson Licensing | Method and apparatus for fusion of images |
US9746595B2 (en) | 2012-06-25 | 2017-08-29 | Jsr Corporation | Solid-state image capture element optical filter and application thereof |
KR101446309B1 (ko) | 2012-07-06 | 2014-10-07 | (주)케비젠 | 공액리놀레산을 생산하는 비피도박테리움 애니말리스 균주 및 그 용도 |
KR101401530B1 (ko) | 2012-07-06 | 2014-06-11 | (주)케비젠 | 공액리놀레산을 생산하는 비피도박테리움 롱검 균주 및 그 용도 |
-
2016
- 2016-09-27 KR KR1020160124270A patent/KR101765559B1/ko active IP Right Grant
-
2017
- 2017-02-16 US US16/337,263 patent/US11229672B2/en active Active
- 2017-02-16 CN CN201780073282.XA patent/CN111278300A/zh active Pending
- 2017-02-16 WO PCT/KR2017/001729 patent/WO2018062643A1/ko active Application Filing
- 2017-09-27 TW TW106133484A patent/TW201834673A/zh unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020192334A1 (en) * | 2001-05-07 | 2002-12-19 | Biohub Co., Ltd | Method for preparing lactic acid fermented solution of mushroom and lactic acid fermented solution of mushroom produced thereby |
KR20030070799A (ko) * | 2002-02-26 | 2003-09-02 | 주식회사 국순당 | 지방질, 다당류 및 단백질에 의하여 2중으로 미세캡슐화된유산균 제품의 제조방법 |
US20070128178A1 (en) * | 2002-07-23 | 2007-06-07 | Nestec S.A. | Probiotics for gut neuromuscular functions |
US20100166721A1 (en) * | 2006-06-09 | 2010-07-01 | Fabiola Masri | Probotic compositions and uses thereof |
CN101579110A (zh) * | 2008-12-05 | 2009-11-18 | 王星丽 | 食用菌休闲食品 |
US20120207712A1 (en) * | 2009-01-12 | 2012-08-16 | Pfizer Italia S.R.L. | Compositions Comprising Probiotic and Prebiotic Components and Mineral Salts, with Lactoferrin |
JP2010285421A (ja) * | 2009-05-15 | 2010-12-24 | Daiso Co Ltd | 腸管免疫賦活能を有する乳酸菌に対する効果促進剤 |
CN102919850A (zh) * | 2012-05-21 | 2013-02-13 | 孟令刚 | 一种用于营养食品及药品的组合物 |
CN104719887A (zh) * | 2013-12-23 | 2015-06-24 | 无锡伟康生物科技有限公司 | 一种调节肠道菌群复合益生菌粉 |
CN104887647A (zh) * | 2014-03-08 | 2015-09-09 | 复旦大学 | 益生菌双层微胶囊及其制备方法 |
CN104544086A (zh) * | 2015-01-23 | 2015-04-29 | 绍兴上虞宏晟技术转让服务有限公司 | 一种可改善肠道菌群的保健食品及其制备方法 |
CN105901697A (zh) * | 2016-04-15 | 2016-08-31 | 邵素英 | 一种真菌提取物益生菌功能性食品 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113456704A (zh) * | 2021-06-22 | 2021-10-01 | 四川省农业科学院土壤肥料研究所 | 一种具有改善肠胃功效的药物组合物及其制备方法和应用 |
CN115462532A (zh) * | 2022-07-28 | 2022-12-13 | 纽崔丝达食品科技(上海)有限公司 | 一种治疗妊娠呕吐的活性益生菌配方及其制备方法 |
CN115153030A (zh) * | 2022-09-08 | 2022-10-11 | 同芙集团(中国)股份有限公司 | 一种益生菌组合物及其应用、益生菌产品及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20200030395A1 (en) | 2020-01-30 |
KR101765559B1 (ko) | 2017-08-07 |
US11229672B2 (en) | 2022-01-25 |
WO2018062643A1 (ko) | 2018-04-05 |
TW201834673A (zh) | 2018-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111278300A (zh) | 包含猴头菇的益生菌组合物 | |
EP2934557B1 (en) | Strain of bifidobacterium animalis ssp. animalis | |
DK2478910T3 (en) | ANTI-ADIPOSITY AGENT, ANTI-ADIPOSITA NUTRITION OR DRINK, GLUCOSE TOLERANCE EFFECTIVE AGENT, AND NUTRITION OR DRINK FOR IMPROVING GLUCOSE TOLERANCE | |
CN108783462A (zh) | 一种肠道益生菌制剂的工业生产方法 | |
CN108936676A (zh) | 包含用于分解酒精或乙醛的益生菌的组合物 | |
CN111956676A (zh) | 一种包含人参提取物和益生菌的微生态制剂及其制备方法和应用 | |
Tomičić et al. | Beneficial properties of probiotic yeast Saccharomyces boulardii | |
KR20220047875A (ko) | 비피도박테리움 브리브 207-1 및 이의 용도 | |
WO2022206300A1 (zh) | 可促进排便的组合物及其用途 | |
US20230104564A1 (en) | Culture process for enhancing proliferation of lactic acid bacteria by using red ginseng | |
TWI785815B (zh) | 用於促進益生菌生長的方法 | |
JP2007082403A (ja) | ユッカ抽出物、キラヤ抽出物及び乳酸菌の複合組成物を含有する飲食品及びその製造法 | |
JP2005013211A (ja) | 乳酸菌含有食品組成物 | |
CN110150526A (zh) | 固体饮料及其制备方法 | |
KR101193602B1 (ko) | 쑥을 탄소원으로 생육가능한 미생물 및 그 용도 | |
US20220192246A1 (en) | Composition and method for synbiotics supplement containing probiotics, digestive enzymes, prebiotics, yeast, protein, b vitamins, and flavoring agent | |
CN107836721A (zh) | 一种具有胃肠道保健功能的组合物及其制备方法 | |
Jung et al. | Synergistic antimicrobial effect of Achyranthes japonica Nakai extracts and Bifidobacterium supernatants against Clostridium difficile | |
KR100973977B1 (ko) | 신규한 락토바실러스 속 미생물 및 이의 용도 | |
JP5980785B2 (ja) | 新規ビフィズス菌及びその利用 | |
Bhattacharyya | Emergence of probiotics in therapeutic applications | |
Rogelj | Lactic acid bacteria as probiotics | |
CN117106628B (zh) | 一种具有免疫调节能力的嗜酸乳杆菌la15及其应用、产品与方法 | |
CN107712074A (zh) | 一种复合益生菌咀嚼片的加工方法 | |
CN115960737A (zh) | 用于促进益生菌生长的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200612 |
|
RJ01 | Rejection of invention patent application after publication |